Breast Cancer: Research
(asked on 4th February 2022) - View Source
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, whether his Department has (a) commissioned research on and (b) allocated funding to research on Triple Negative Breast Cancer.
Answered by
Maria Caulfield
Parliamentary Under Secretary of State (Department for Business and Trade) (Minister for Women)
The Department invests in health research through the National Institute for Health Research (NIHR). The following table shows the research projects on triple negative breast cancer funded by the NIHR since 2019/20.
Award title | Award budget |
Atezolizumab with nab-paclitaxel for untreated PD L1-positive, locally advanced or metastatic, triple-negative breast cancer [ID1522] | £65,625 |
Pembrolizumab in combination for untreated, locally recurrent inoperable or metastatic, triple negative breast cancer [ID1546] | £65,625 |
Atezolizumab (neoadjuvant, with nab-paclitaxel) for early, triple negative breast cancer (ID1574) | £65,625 |
Sacituzumab govitecan for treating unresectable locally advanced or metastatic triple-negative breast cancer after two or more therapies ID3942 | £65,625 |
The NIHR is also supporting the delivery of triple negative breast cancer research funded by research partners in the charity and public sectors. In 2020/21, the NIHR Clinical Research Network has supported approximately 25 related studies into triple negative breast cancer. With Cancer Research UK, the NIHR is jointly funding a network of Experimental Cancer Medicine Centres for the discovery and early-phase clinical testing of new anti-cancer treatments, including immunotherapy. As with other Government funders of health research, the NIHR does not allocate funding for specific disease areas. The level of research spend in a particular area is determined by factors including scientific potential and the number and scale of successful funding applications.